101 related articles for article (PubMed ID: 14709327)
1. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol.
Marchese G; Bartholini F; Ruiu S; Casti P; Casu GL; Pani L
Eur J Pharmacol; 2004 Jan; 483(1):65-9. PubMed ID: 14709327
[TBL] [Abstract][Full Text] [Related]
2. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Marchese G; Casu MA; Bartholini F; Ruiu S; Saba P; Gessa GL; Pani L
Eur J Neurosci; 2002 Apr; 15(7):1187-96. PubMed ID: 11982629
[TBL] [Abstract][Full Text] [Related]
3. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant strategy to counteract the side effects of antipsychotic therapy: an in vivo study in rats.
Besret L; Caldwell MA; Torres EM; Dunnett SB
Eur J Pharmacol; 2000 Nov; 408(1):35-9. PubMed ID: 11070181
[TBL] [Abstract][Full Text] [Related]
5. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Bachus SE; Yang E; McCloskey SS; Minton JN
Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
[TBL] [Abstract][Full Text] [Related]
6. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat.
Levinson AJ; Garside S; Rosebush PI; Mazurek MF
Neuroscience; 1998 May; 84(1):201-11. PubMed ID: 9522374
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
Datta S; Jamwal S; Deshmukh R; Kumar P
Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
[TBL] [Abstract][Full Text] [Related]
9. Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior.
Saldaña M; Bonastre M; Aguilar E; Marin C
Exp Neurol; 2007 Feb; 203(2):302-8. PubMed ID: 17069804
[TBL] [Abstract][Full Text] [Related]
10. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
[TBL] [Abstract][Full Text] [Related]
12. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
13. Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal.
Mazurek MF; Savedia SM; Bobba RS; Garside S; Rosebush PI
J Neurol Neurosurg Psychiatry; 1998 Jun; 64(6):799-801. PubMed ID: 9647315
[TBL] [Abstract][Full Text] [Related]
14. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY
Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817
[TBL] [Abstract][Full Text] [Related]
15. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
Meshul CK; Andreassen OA; Allen C; Jørgensen HA
Psychopharmacology (Berl); 1996 Jun; 125(3):238-47. PubMed ID: 8815959
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
Zhang Y; Xu H; He J; Yan B; Jiang W; Li X; Li XM
Neurosci Lett; 2007 Jun; 420(1):66-71. PubMed ID: 17466452
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH
Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413
[TBL] [Abstract][Full Text] [Related]
18. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
Haleem DJ; Samad N; Haleem MA
Behav Pharmacol; 2007 Mar; 18(2):147-53. PubMed ID: 17351421
[TBL] [Abstract][Full Text] [Related]
19. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
Andreassen OA; Ferrante RJ; Aamo TO; Beal MF; Jørgensen HA
Neuroscience; 2003; 122(3):717-25. PubMed ID: 14622915
[TBL] [Abstract][Full Text] [Related]
20. Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias.
Kelley JJ; Roberts RC
J Neural Transm (Vienna); 2004 Aug; 111(8):1075-91. PubMed ID: 15254795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
